Primary source: InTandem via Business Wire, October 29, 2026 · InTandem Capital Partners

InTandem Invests in Atlas Health. Financial Clearance Is Becoming Front-End Revenue Cycle Infrastructure.

InTandem Capital Partners has completed a strategic growth investment in Atlas Health, an AI-powered platform that matches and enrolls hospital and health-system patients in affordability programs. Atlas management keeps leading the company and remains a significant shareholder alongside InTandem. The amount, valuation and ownership stake were not disclosed.

InTandem announced the completed investment on October 29, 2026, from New York, on Business Wire. The firm posted the same release the same day. The two texts match. This article uses those primary accounts. It does not estimate a price the parties left out.

What the Close Actually Establishes

InTandem Capital Partners, LP is described as a healthcare-focused private equity firm. Atlas Health, founded in 2017, partners with hospitals and health systems to match and enroll patients in healthcare affordability programs that the release says increase coverage and reimbursement while improving patient access, satisfaction and clinical outcomes. The company calls itself an industry-leading AI-powered platform for patient affordability. That ranking is the company's language. The release does not name a comparison set.

The operating product named in the release is Ava, which Atlas calls its proprietary agentic AI. The company says it is helping millions of patients facing costly treatments find financial assistance. "Millions" is a company-reported scale statement. The release does not give a hospital count, a patient-panel definition, revenue, or a list of clients.

The Category the Parties Are Naming

Ethan Davidoff, founder and CEO of Atlas Health, stated: "Patient affordability is becoming a category every health system runs on dedicated infrastructure. We built that infrastructure. From the EHR integrations to the agentic AI that does the work, it spans revenue cycle and pharmacy alike: coverage, enrollment, medication access, and financial assistance. This investment is about finishing the job, making financial clearance as automatic as an insurance check in every health system in the country, and extending that same infrastructure to the specialty pharmacies that fund and deliver patient access."

That paragraph is the operating thesis, and it is his. Financial clearance, in the way a revenue-cycle department already uses the term, is the work of knowing how an encounter will be paid before the claim depends on it. An eligibility check answers a narrower question: is this coverage on file, and is it active? The work Davidoff lists sits beside that check. Coverage and enrollment ask whether a patient can be placed into a program that creates a payer. Medication access and financial assistance ask whether a drug or a balance has a funding path other than self-pay. The release does not itemize Medicaid, marketplace exchange, charity care, manufacturer copay or hospital financial-assistance policy as separate modules. Those are the programs a health-system financial-clearance shop usually means by "affordability." Atlas's release uses the broader labels. Operators should not read a program list the source does not give.

The company description adds three more claims, all Atlas's. The platform is "proactive coverage enrollment automation." It consists of "a large integrated funding network" and "advanced workflow automation software powered by AI agents and expert advocates." Organizations that partner with Atlas, the release says, get a streamlined financial clearance process, high levels of insurance reimbursement and reduced uncompensated care. None of those outcomes is quantified. Reduced uncompensated care is the revenue-cycle result that would make the category matter. The release asserts the direction. It does not show a baseline, a method or a dollar result.

Why a Healthcare PE Firm Is Backing It

Brad Coppens, president and managing partner at InTandem, stated: "Regulatory reform and employer healthcare cost escalation are impacting coverage for millions while specialty drug costs continue their unrelenting rise. As a result, helping patients navigate the financial burden of care is transitioning from a back-office afterthought to a critical front-line revenue recovery tool, and we believe Atlas has built the most capable platform in the category." He added: "Atlas is positioned to be an important part of the solution. We are thrilled to partner with Ethan and the Atlas Health team to further strengthen the Company's leadership in patient affordability."

Aaron Newman, principal at InTandem, stated: "We have followed the patient affordability space for several years, and Atlas has consistently set the standard for the category. Ethan and team have built a platform that removes ineffective, manual, and fragmented processes and delivers clear ROI for health systems and real impact for patients. We look forward to supporting Atlas Health's next phase of growth through product innovation and market expansion."

"Clear ROI" and "most capable platform" are the investor's conclusions. The release does not publish the return, the cost to collect, the conversion rate from match to enrolled coverage, or the competitors Newman has followed. What the quotes do establish is the reason InTandem says it wrote the check: coverage is getting harder, specialty drugs keep getting more expensive, and the firm wants the workflow that finds a funding path treated as revenue recovery rather than as a back-office courtesy.

The structure fits that thesis better than a buyout announcement would. Management continues to lead. Management remains a significant shareholder alongside the new investor. InTandem's own description says it invests in select healthcare services companies, works with management partners, and provides strategic acquisition and operating expertise. The release does not announce an add-on acquisition, a new platform brand, or a change of CEO. The capital is for a company that stays independently led.

InTandem says its investing lens is the Healthcare Quintuple Aim: patient experience, provider experience, clinical outcomes, equity and lower cost of care delivery. That is the firm's stated filter. It is not evidence that Atlas has moved any of those measures.

The stated plan for the capital is narrow, and it should stay narrow in any retelling. Atlas plans to accelerate key product initiatives and invest further in serving providers and patients. Davidoff's version of the same plan is to make financial clearance as automatic as an insurance check in every health system, and to extend that infrastructure to the specialty pharmacies that fund and deliver patient access. Specialty pharmacy is a stated extension. This release does not say it is live, name a pharmacy partner, or describe the workflow on that side of the counter.

Where This Sits in the Front End

Revenue cycle teams already buy pieces of this problem under older names. Insurance discovery searches for coverage the registration file missed, including after the encounter. Medicaid enrollment and renewal try to turn an eligible uninsured patient into a payable account before the balance becomes bad debt. Charity care and hospital financial assistance write down the balances the mission says should not be collected. Manufacturer and foundation programs do a version of the same job for a drug. Atlas's release folds coverage, enrollment, medication access and financial assistance into one platform and calls the result financial clearance.

That bundling is the strategic point, independent of the missing price. A health system can staff each of those workflows in a different office: patient access runs eligibility, a foundation office runs drug assistance, financial counseling runs charity care, and the specialty pharmacy runs its own benefit investigation. The CEO's claim is that one infrastructure, tied to the EHR and run in part by an agent, covers the set. If that claim is true in production, the buyer is the revenue-cycle owner, not a grant writer. If it is a bundle of referrals across programs, it is a services layer with a software front end. The release supports the ambition. It does not show the production map.

Two adjacent moves already on the RevCycleAI record show why the buyer is paying attention, and they are not evidence about Atlas. Experian's acquisition of eInsights extended insurance discovery past the first eligibility check into post-service coverage search. R1's partnership with Fortuna Health put Medicaid enrollment and renewal inside financial clearance. Atlas is not described as either of those products. The pattern is the pattern: capital and large RCM operators are treating "can this patient be covered or assisted?" as revenue-cycle work.

Ava is the part of the story most likely to be over-read. The release calls it proprietary agentic AI that "does the work," inside EHR integrations, across coverage, enrollment, medication access and financial assistance. The company description says the software is powered by AI agents and expert advocates. Agents plus advocates is a human-in-the-loop design, which is the responsible shape for an enrollment decision a payer or a state still has to approve. The release does not say which decisions Ava completes, which it drafts, or which an advocate must sign. It does not mention a model, a denial rate, or an audit trail.

What Operators Should Watch

Four questions decide whether this close changes a health system's front end. None of them is answered in the source.

1. Which programs are actually in the workflow. "Affordability programs" can mean presumptive charity care, Medicaid, a marketplace plan, a manufacturer copay card, a foundation grant, or a hospital payment plan. Yield, compliance and patient experience are different in each. A revenue-cycle leader should ask for the program list, the states, and who submits the application.
2. Match versus enrolled coverage. Matching a patient to a program is a lead. Enrolled, effective coverage that a biller can put on a claim is cash. The release says Atlas does both. It does not define when a match counts, or how often a match becomes a payer ID in the EHR.
3. What "significant shareholders" means for control. Management is still leading. InTandem is now a shareholder and says it provides operating support to portfolio companies. Governance, board seats and any reserved matters were not disclosed. A health system signing a multi-year financial-clearance contract will care who can sell the company next.
4. The specialty-pharmacy extension. Hospital financial clearance and specialty-pharmacy benefit investigation share data and do not share an owner. Davidoff says the same infrastructure should reach the pharmacies that fund and deliver access. Until a pharmacy workflow, a data share and a reimbursement result are public, that line is a product plan.

A fifth check is the advisor set, and it is the one fact that is public. J.P. Morgan was Atlas's exclusive financial advisor. Cooley advised Atlas. Greenberg Traurig advised InTandem. That is the advisor staffing of the investment. It still does not disclose proceeds, rollover percentage or a go-forward board.

What Has Been Verified, and What Has Not

The Business Wire release and InTandem's matching post establish the parties, the October 29, 2026 date, the completed growth investment, management continuity, the significant-shareholder line, the 2017 founding, the hospital and health-system customer, Ava, the four-part scope of coverage, enrollment, medication access and financial assistance, the product and specialty-pharmacy plans in Davidoff's statement, the three executive statements quoted above, and the three advisors.

The same sources do not disclose price, valuation, stake, revenue, earnings, a client or hospital count, a definition of "millions of patients," a measured change in uncompensated care, an ROI figure, a named EHR, a named specialty-pharmacy customer, or a competitive ranking anyone other than the parties has made. Company descriptions of a funding network, expert advocates, reimbursement levels and uncompensated-care reduction are Atlas's. The Quintuple Aim is InTandem's.

RCAI Take

Private equity just funded patient affordability as front-end revenue-cycle infrastructure, and it did so without publishing a price. The work Atlas describes — finding a coverage or assistance path, then enrolling the patient — is the step that decides whether a balance is a claim or uncompensated care. InTandem's stated reason for backing it is that coverage friction and specialty-drug cost have moved that step out of the back office.

The analytical limit is the same as the disclosure limit. Until amount, stake and a measured conversion from match to paid claim are public, the close is evidence that a healthcare investor wants the category, not evidence of what the category is worth or of how Ava performs. Revenue-cycle leaders should read the program list, the enrollment definition and the governance line before they treat financial clearance as a settled platform layer.

Sources: InTandem Capital Partners via Business Wire, October 29, 2026; InTandem Capital Partners, October 29, 2026. Quotes are verbatim from the release. "Millions of patients," reimbursement levels, uncompensated-care reduction, ROI and category ranking are company or investor statements and are labeled as such. Amount, valuation and stake were not disclosed. Front-end revenue-cycle implications are RevCycleAI analysis. Adjacent coverage: Experian / eInsights; R1 / Fortuna.